From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The fraud Supply@Me Capital – looking at the murky Tradeflow deal from the perspective of Tom James and John Collis

By Tom Winnifrith | Saturday 1 July 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


We know that Supply@ME Capital (SYME) paid £4,000,000 in cash and issued 813,000,000 shares to Tom James and John Collis for the acquisition of Tradeflow Capital. Following the issue of the 2021-year end accounts, SYME issued the two vendors a further 213,525,520 shares as deferred consideration which resulted in total holding of 1,026,525,520 shares. Under the vendors buy back of 81% of Tradeflow, Alessandro Zamboni’s AvantGarde (TAG) paid £2,000,000 for the 1,026,525,520 shares held by Tom James and John Collis as described below:
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:46:08